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Abstract
Background: It is desirable in genomic studies to select biomarkers that diﬀerentiate between normal and diseased
populations based on related data sets from diﬀerent platforms, including microarray expression and proteomic data.
Most recently developed integration methods focus on correlation analyses between gene and protein expression
proﬁles. The correlation methods select biomarkers with concordant behavior across two platforms but do not
directly select diﬀerentially expressed biomarkers. Other integration methods have been proposed to combine
statistical evidence in terms of ranks and p-values, but they do not account for the dependency relationships among
the data across platforms.
Results: In this paper, we propose an integration method to perform hypothesis testing and biomarkers selection
based on multi-platform data sets observed from normal and diseased populations. The types of test statistics can
vary across the platforms and their marginal distributions can be diﬀerent. The observed test statistics are aggregated
across diﬀerent data platforms in a weighted scheme, where the weights take into account diﬀerent variabilities
possessed by test statistics. The overall decision is based on the empirical distribution of the aggregated statistic
obtained through random permutations.
Conclusion: In both simulation studies and real biological data analyses, our proposed method of multi-platform
integration has better control over false discovery rates and higher positive selection rates than the uncombined
method. The proposed method is also shown to be more powerful than rank aggregation method.
Background
In gene expression experiments, the expression levels of
thousands of genes are simultaneously monitored to study
the underlying biological process. In proteomic data, the
protein levels or protein counts are measured for thou-
sands of genes simultaneously. In addition, there are other
types of genomic data with diﬀerent sizes, formats and
structures. Each distinct data type, such as gene expres-
sion, protein counts, or single nucleotide polymorphisms,
provide potentially valuable and complementary informa-
tion regarding the involvement of a given gene in a biolog-
ical process. Many biomarkers that play important roles in
biological processes behave diﬀerently in treatment versus
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control groups; this phenomenon can be observed consis-
tently across various data platforms. Therefore, integrat-
ing related data sets from diﬀerent sources is crucial to
correctly identify the signiﬁcant underlying biomarkers.
Integrative analysis of multiple data types would improve
the identiﬁcation of biomarkers of clinical end points [1].
However, the integration of data from diﬀerent sources
poses a number of challenges. First, genomic data come
in a wide variety of data formats. For example, expression
data are recorded as continuous measurements, whereas
proteomic data often consist of discrete counting vari-
ables. One may wish to convert data into a common
format and common dimension, but this is not always
practical or feasible [2]. Second, diﬀerent data sets are col-
lected under diﬀerent experimental settings. Therefore,
the distribution of the measurements as well as the qual-
ity of the experiments may vary from data set to data
set. Third, measurements obtained across diﬀerent data
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platforms could be collected from the same or related
biological samples. Therefore, measurements across dif-
ferent data types could have complicated dependency
relationships.
The practice of combining diﬀerent data sources to per-
form classiﬁcation analysis has been considered in the
literature. Eﬀorts to integrate data and improve classiﬁca-
tion accuracy are widely seen in recent studies [3-5]. In
contrast to performing classiﬁcation on biological sam-
ples, our main objective is to select important biomarkers
for an underlying biological process. Correlation analy-
sis has been proposed to integrate diverse data types and
assimilate them into biological models for the prediction
of cellular behavior and clinical outcome. Tian et al. [6]
performed a correlation analysis of protein and mRNA
expression data using the cosine correlation metric for
comparison. Bussey et al. [7] integrated data on DNA copy
number with gene expression levels and drug sensitivities
in cancer cell lines based on Pearson’s correlation coeﬃ-
cients. Adourian et al. [8] presented a cross-compartment
correlation network approach to integrate proteomic,
metabolomic, and transcriptomic data for selecting circu-
lating biomarkers; partial pairwise Pearson’s correlations
controlling for treatment group means were calculated.
The markers with concordant RNA and protein expres-
sion were included in the prediction models, while dis-
cordant ones were excluded. However, this approach
might miss some important biological information, such
as protein-protein interactions and protein-gene interac-
tions [9]. Another limitation is that correlation analysis
mainly captures the strength of the correlation among
measurements across diﬀerent platforms; however, strong
correlation only demonstrates consistent outcome across
diﬀerent platforms and does not directly translate to sig-
niﬁcant involvement in a biological process. Furthermore,
statistical evidence from complicated data sets, such as
factorial experiments, times series, or longitudinal data,
cannot be summarized.
The problem of how to reliably combine data from
diﬀerent experiment platforms to identify signiﬁcant
biomarkers has recently received considerable attention
in the bioinformatics literature. The rank aggregation
method [10] has been proposed for ranking genes by sim-
ilarity to the disease genes in Gene Ontology, pathways,
transcription factor binding sites, and sequence, then
aggregating this rankings to get the ﬁnal result. Rhodes
et al. [11] combined four independent data sets to iden-
tify genes deregulated in prostate cancer. For each gene in
each data set, a p-value was obtained as an indication of
the probability that the gene was diﬀerentially expressed.
P-values for diﬀerent data sets were subsequently aggre-
gated to provide an overall estimate of the genes’ signif-
icance of being diﬀerentially expressed during prostate
cancer. However, combining genes’ ranks in the rank
aggregation approach or p-values in the meta-proﬁling
method ignores the underlying multivariate distributions
of the ranks or p-values. Furthermore, data quality may
vary across diﬀerent data sources. The two aggregation
methods detailed above essentially give equal weights to
diﬀerent data sets. Thus, we propose to combine statisti-
cal evidence across diﬀerent platforms through summary
statistics instead of raw data. For each experimental plat-
form, we formulate a null hypothesis and construct the
summary test statistic. By randomization, we obtain the
null distribution of the vector of statistics across diﬀerent
platforms. The test statistics are summarized across dif-
ferent platforms in a weighted scheme, where the weights
take into account diﬀerent variabilities possessed by the
statistics. The method allows the use of diﬀerent types
of summary statistics from diﬀerent platforms, which
gives great ﬂexibility and generality with respect to its
application.
The proposed method is similar in spirit to a meta-
analysis. Both methods combine statistical evidence
across multiple data sets. However, in meta-analysis dif-
ferent data sets are based on the same type of experiments
or observational studies, and therefore the measurements
are the same variables. Across diﬀerent data sets, the
quality of the data may vary. The goal of meta-analysis
is to fully utilize all the information from diﬀerent data
sets and construct a weighted estimate of the eﬀect size.
Diﬀerent weighting schemes are available depending on
the statistical models [12]. On the other hand, data inte-
gration focuses on integrating statistical evidence across
diﬀerent experimental types. There is no common eﬀect
size to estimate across various data sets. In our proposed
method, we use a weighted average of the test statistics
across diﬀerent data platforms, but the test statistics are
summaries of evidence towards diﬀerent sub-hypotheses
rather than summaries of common eﬀect size as in meta-
analysis. The proposed integrationmethod does not check
for diﬀerences across the platforms.
Methods
The aim of our multi-platform integration method is to
select a set of signiﬁcant biomarkers that are involved
in a biological process and thus behave diﬀerently in
the treatment group and the control group. In order to
combine statistical evidence across diﬀerent platforms,
our method requires that analogous hypotheses based
on the features being measured are formulated for each
platform. Each null analogous hypothesis speciﬁes the
unrelatedness of the biomarker in that particular exper-
imental setting, but all of them infer the unrelatedness
of the biomarker to the biological process being investi-
gated. Based on the set of Q analogous hypotheses for Q
data sources, we construct a set of Q corresponding test
statistics for each type of data. The test statistics can be
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diﬀerent and tailored to the speciﬁc experimental settings.
For example, if the microarray experiment has a multi-
factorial design, the appropriate test statistic can be an
F statistic based on an ANOVA test. If the proteomics
experiment generates counting data for diseased versus
normal groups, the appropriate test statistic can be a non-
parametric Wilcoxon rank sum test. A vector of observed
statistics across multi-platforms is obtained. We then ran-
domly permute data across diseased and control groups.
All measurements from diﬀerent platforms are permuted.
In this way, we obtain an empirical null distribution of the
vector of test statistics. In order to pool the randomized
values of the statistics across the biomarkers to form the
empirical null distribution, we assume data from diﬀerent
biomarkers are independent or have an exchangeable cor-
relation structure. For the validity of the randomization
procedure, we assume an exchangeable covariance struc-
ture for the measurements within each platform. Finally,
we construct a weighted sum of the test statistics across
diﬀerent platforms with the weights being the inverse
of the empirical standard deviation of each statistic. We
determine a set of signiﬁcant biomarkers based on the
aggregated test statistic.
In the following, we demonstrate our method by inte-
grating microarray expression data and proteomic data as
an example. We consider two experiments, the ﬁrst hav-
ing microarray expression data measured on l1 diseased
samples and l2 control samples and the second having
proteomic data measured on m1 diseases samples and
m2 control samples. The objective is to ﬁnd biomarkers
signiﬁcantly involved in disease development.
Step 1): Deﬁne two analogous null hypotheses. For
microarray data, the null hypothesis would be H01 :
the gene’s mRNA level is the same in diseased and
normal populations; for proteomic data, the null
hypothesis would be H02 : the protein level is the
same in diseased and normal populations.
Step 2): Based on the hypotheses, construct two test
statistics, tm and tp, tailored to each type of data.
Consequently, we obtain a vector of two observed
statistics (tm, tp)′ across two data platforms. The test
statistics can be of any type as long as they
summarize information from the data and can be
used to assess the statistical signiﬁcance of the data
toward the hypotheses. Let x1 = (x11, . . . , x1l1)′
denote the l1 gene expression measurements in the
disease group, x2 = (x21, . . . , x2l2)′ denote the l2 gene
expression measurements in the control group,
x1 =∑l1j=1 x1j/l1, and x2 =
∑l2
j=1 x2j/l2. Similarly,
y1 = (y11, . . . , y1m1)′ denotes them1 protein
measurements in the disease group and
y2 = (y21, . . . , y2m2)′ denotes them2 protein
measurements in the control group,
y1 =
∑m1
j=1 y1j/m1, and y2 =
∑m2
j=1 y2j/m2. For
illustration purpose, we adopt Student’s t-statistic for
each of the data:













where s2 denotes the sample variance. The test
statistics should be formulated so that a larger test
statistic in the positive direction indicates more
evidence towards the alternative hypotheses. For
example, if Student’s t-statistic is used, then a
one-sided alternative hypothesis corresponds to a
one-sided t-statistic, whereas the two-sided
alternative leads to the absolute value of the
t-statistic. Consider n genes being measured in the
experiments and we obtain n vectors of test statistics
(tmi, tpi)′, i = 1, . . . , n, from the data sets.
Step 3): The samples are randomly permuted across
diseased and control groups. If the same sample is
being measured across diﬀerent platforms, all the
measurements from the diﬀerent platform are
permuted simultaneously. The simultaneous
permutation preserves the dependency relationship
among the measurements from diﬀerent platforms.
Based on random permutation, we obtain an
empirical null distribution of the vector (tm, tp)′.






where σˆ1 and σˆ2 are the estimated standard
deviations of tm and tp based on the empirical null
distribution, and tm and tp are the observed
t-statistics or the absolute values of the t-statistics
based on the direction of the alternative hypotheses.
At signiﬁcance level α, we choose a threshold Cα ,
such that PH01∩H02(tA > Cα) = α. Speciﬁcally, Cα is
the 100(1 − α)% percentile of tA, which can be
obtained from the empirical null distribution.
Construct a decision line that separates selected
signiﬁcant biomarkers and nonsigniﬁcant






All the biomarkers with (tm, tp) above the separation
line will be declared as signiﬁcantly involved in the
disease development.
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In the more general case, suppose we have Q data plat-
forms with the observed test statistics (t1, . . . , tQ)′. From
random permutation, we obtain the joint empirical distri-
bution of this vector of test statistics under the global null
hypothesis. Let σˆ 21 , . . . , σˆ 2Q denote the estimated variance








The resulting critical region will take the form:
t1
σˆ1
+ .... + tQ
σˆQ
> Cα ,
where Cα is the 100(1 − α)% percentile of tA. Any
biomarker with tA > Cα will be selected as behaving
signiﬁcantly diﬀerently between the diseased group and
control group.
Our method aggregates actual values of the test statis-
tics across diﬀerent data platforms, which preserves more
information compared to the rank aggregation method.
Moreover, our method assigns diﬀerent weights to each
data set according to the variability of the test statis-
tics: larger the variation in the test statistic, the smaller
the weight assigned to it, and vice versa. The threshold
Cα is determined based on the empirical null distribu-
tion of the aggregated test statistics, which implicitly takes
into account the dependency relationships among the
test statistics. Furthermore, our method can deal with
diﬀerent data types and formats generated by various
experimental settings.
There are two major ways to perform the multiplicity
adjustment. The ﬁrst is the Bonferroni correction. If we
wish to control the familywise type I error rate at α∗, then
the individual level α = α∗/n, where n is the total number
of biomarkers. When n is large, the Bonferroni correction
leads to very stringent tests with α being very small. Alter-
natively, we can control the number of false discoveries.
To set the number of false discoveries to be equal to or less
than f, then α = f /(nπˆ), where πˆ is the estimated propor-
tion of non-diﬀerentially expressed biomarkers. If there is
no πˆ available, we use πˆ = 1 and that gives a conservative
value for α.
Diﬀerent platforms can be used to test diﬀerent sub-
hypothesis. All of these sub-hypotheses should be con-
cordant in supporting the overall biological hypothesis.
For example, the involvement of a gene in disease devel-
opment can be supported by both mRNA expression
level changes and proteomic level changes. In most cases,
changes in measurements from diﬀerent platforms are
expected to occur in the same direction. However, our
method is also applicable even if the changes are in diﬀer-
ent directions, as long as the statistical evidence from both
sources can be combined. For example, consider H10 :
mRNA is increasing in normal group;H20: antibody count
is decreasing in normal group. Even though the actual
measurements from two platforms are negatively corre-
lated, we can construct the test statistics t1 and t2 so that
the positive value of the statistics supports the alternative
hypotheses and the weighted average can be used as com-
bined evidence of the involvement of the biomarker in the
process.
Results
Results on simulated data
In this section, we examine the performance of our pro-
posed method by examining its positive selection rates
and false discovery rates under various testing scenarios.
We simulate data sets from Q diﬀerent platforms. The
number Q is set to be either 2 or 5. For the qth exper-
iment, the data set is denoted as Xq. For each data set,
we assume that n diﬀerent biomarkers are measured,
Xq = (X′q1, . . . ,X′qn)′. For the ith biomarker, Xqi =
(X′qi1,X′qi2)′, where Xqi1 denotes data from the control
group with mean μqi1 and Xqi2 denotes data from the
diseased group with mean μqi2. The total number of
biomarkers is set to be n = 1000. Among the n biomark-
ers, let g denote the number of biomarkers that are related
to the biological process of interest, i.e. μqi1 = μqi2.
The number g of diﬀerentially expressed (DE) biomark-
ers is set to be 200. The number of measurements for
each biomarker obtained from each platform is set to be
10, in which 5 are from the control group and the other
5 are from the disease group. We also consider diﬀerent
eﬀect sizes. For continuous data, we generate Xqi ∼MVN(
(μ′qi1,μ′qi2)′, ), where  has an exchangeable correlation
structure with correlation ρ. The correlation ρ is set to
be either 0 or 0.5. For diﬀerentially expressed markers,
μqi1 = 0 × 1m, μqi2 = e × 1m, where e is the eﬀect size
andm = 5 is number of measurements. Discrete data Xqi
is generated from a Poisson(λ) distribution, where λqi1 =
μqi1 for the control group and μqi2 = μqi1 + e for the
diseased group. The g diﬀerentially expressed markers are
divided into two groups with g1 = 100 and g2 = 100. Each
group is assigned a diﬀerent eﬀect size e. For each plat-
form, the alternative hypothesis can be either left-sided,
right-sided or two-sided. The number of permutation is
100. All of the permuted values from the n biomarkers are
pooled together to form the empirical null distribution.
The results are summarized for 100 simulated data sets.
To compare our multi-platform integration method
with the individual platform analysis method, the posi-
tive selection rate (PSR) and false discovery rate (FDR) are
calculated to assess the performance of each method for
selecting the diﬀerentially expressed biomarkers:
PSR = # of correctly identiﬁed DE biomarkers# of DE biomarkers
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and
FDR = # of falsely identiﬁed DE biomarkers# of identiﬁed DE biomarkers
Tables 1, 2, and 3 provide detailed simulation settings
and results at the α = 0.05 signiﬁcance level. From the
results, we can see that our multi-platform integration
method has the highest PSR and the lowest FDR with the
smallest variance compared to all other individual plat-
form analyses in all scenarios. In addition, such advantage
is consistently observed regardless of whether or not there
is correlation among the measurements obtained for each
biomarkers. Table 1 summarizes the results for the inte-
grative analysis based on two diﬀerent platforms. Given
diﬀerent eﬀect sizes, diﬀerent sided alternatives, and dif-
ferent correlations, the increase in PSR is consistently
about 40% and the decrease in FDR is about 30% com-
pared to the results from individual platforms. Table 2
summarizes the results for the integrative analysis based
on ﬁve diﬀerent platforms. Given diﬀerent simulation sce-
narios, the increase in PSR formost cases is about 60% and
the decrease in FDR is about 40% compared to the results
from individual platforms. This shows that by integrat-
ing more data from diﬀerent sources, we are improving
the sensitivity and selectivity of the proposed method.
Table 3 summarizes the results for the integrative analysis
based on two diﬀerent platforms, where the ﬁrst consists
of continuous data and the second consists of discrete
data. Similar to the setting with two continuous data sets,
the increase in PSR is about 40% and the decrease in
FDR is about 30% compared to the results from individual
platforms.
Figure 1 demonstrates decision lines from diﬀer-
ent methods. The plot is constructed based on the
results from one simulated data set and contains three
decision lines: the vertical line using data from the
ﬁrst individual platform, the horizontal line using data
from the second individual platform, and the dashed
line based on our multi-platform integration method.
Our decision line provides a greatly improved separa-
tion of the diﬀerentially and non-diﬀerentially expressed
biomarkers. Moreover, the individual platform analysis
misidentiﬁes some of the data points compared to our
method.
As we examine a large number of biomarkers, we need
to investigate the control of the false discovery rate of
the proposed method with regards to multiple hypoth-
esis testing [13]. Given a ﬁxed cut-oﬀ value of α, we
obtain the realized false discovery rate FDR = (FP)/(TˆP)
and its estimates ˆFDR = (FˆP)/( ˆTP), where FP denotes the
number of false positive biomarkers, FˆP = nπα is the esti-
mated number of false positive biomarkers, TˆP is the total
number of biomarkers claimed as positive, π is the pro-
portion of non-diﬀerentially expressed genes, and πˆ is its
estimator. We can control the estimated number of false
positive discoveries by selecting the signiﬁcance level of
the approaches. We expect that the estimated FˆP should
be close to the true FP; the ˆFDR should be close to the true
FDR as well. Under the simulation setting of scenario 2
left-sided case in Table 1, the control of the false discovery
rate of our proposed method under diﬀerent signiﬁcance
levels is examined and presented in Table 4. With π = 0.8
and α = 0.005, FˆP is aimed to be controlled at 4. On aver-
age, our method produces 3.84 false positives, whereas
the ﬁrst and second individual platform analyses has 4.65
and 5.00 false positives, respectively. The corresponding
average ˆFDR of our method is 0.0225, which is close to
the true FDR of 0.0214. This demonstrates the integra-
tive analysis yields satisfactory control of false discovery
rate, which is improved compared to individual platform
analyses.
Results on real data
In this section, we apply our method to data from a
study of growth and stationary phase adaption in Strepto-
myces coelicolor provided by Jayapal et al. [16]. The data
set contains both isobaric stable isotope labeled peptide
(iTRAQTM)-derived shotgun proteomic data and DNA
microarray transcriptome data. To study diﬀerent growth
stages of S. coelicolorM145 cells, eight time point cell sam-
ples (7, 11, 14, 16, 22, 26, 34, and 38 h) were collected.
Because the iTRQATM system can only analyze four dis-
tinct samples in a single experiment, the eight protein
samples were distributed across three runs of mass spec-
trometric (MS) analysis, The protein sample from 11 h
was run in three MS experiments, so it serves as a ref-
erence. Therefore, protein abundance ratios rij/11hr,k were
obtained from experimental run k for protein i in sample
jhr with respect to the 11 h reference. Protein identiﬁ-
cation and quantiﬁcation were carried out by comparing
the raw spectral data against a theoretical proteome of S.
coelicolor using proteinPilotTM software and the inbuilt
ParagonTM search engine. Only proteins identiﬁed with
≥ 99% conﬁdence were considered for further analysis.
Finally, all identiﬁed proteins were further processed to
yield a protein abundance ratio with respect to the ﬁrst
time point (7 h) sample using rij/7hr = rij/11hr/ri7hr/11hr .
Ultimately, only 886 proteins identiﬁed in the 7 h sample
could be used for our analysis.
For microarray data, total mRNA from the same
eight time point samples were isolated and a spotted
DNA microarray experiment was conducted. Hybridiza-
tion was performed using genomic DNA (gDNA) as a
reference. The mRNA abundance was obtained using
log2[cDNA/gDNA]. To be consistent with the protein
data, mRNA abundance data from diﬀerent samples were
processed to calculate log2[cDNAi/cDNA7hr] for each
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sample with respect to the ﬁrst time point sample. Only
gene expression values with protein values (894 genes)
were analyzed. To deal with missing values, we deleted
genes that had no values for mRNA at all or had at least
ﬁve missing values in the protein data set. The rest of the
missing values for genes were imputed by using R package
MICE. In total, the number of genes suitable for the sub-
sequent integrative analysis was 886. Based on the growth
curve, time points were divided into two groups; those
from 7, 11, 14 and 16 h represented the growth phase and
Table 1 The simulation settings and results for two platforms with continuous data
Methods
Multi-platform 1st individual 2nd individual
Scenario 1: ρ = 0; g = g1 + g2 = 200
Right-side Experiment1: e = 0.5 for g1 = 100; e = 2 for g2 = 100
Experiment2: e = 1.5 for g1 = 100; e = 1 for g2 = 100
PSRMean 0.7895 0.5372 0.5588
PSR Var 0.0007 0.0007 0.0010
FDRMean 0.1907 0.2680 0.2600
FDR Var 0.0007 0.0013 0.0009
Left-side Experiment1: e = -0.5 for g1 = 100; e = -2 for g2 = 100
Experiment2: e = -1.5 for g1 = 100; e = -1 for g2 = 100
PSRMean 0.7908 0.5330 0.5556
PSR Var 0.0006 0.0006 0.0012
FDRMean 0.1891 0.2673 0.2649
FDR Var 0.0006 0.0009 0.0011
Two-sided Experiment1: e = -1 for g1 = 100; e = 1.5 for g2 = 100
Experiment2: e = 2 for g1 = 100; e = -1 for g2 = 100
PSRMean 0.6988 0.4113 0.5403
PSR Var 0.0011 0.0011 0.0010
FDRMean 0.2145 0.3202 0.2694
FDR Var 0.0007 0.0016 0.0012
Scenario 2: ρ = 0.5; g = g1 + g2 = 200
Right-side Experiment1: e = 0.5 for g1 = 100; e = 2 for g2 = 100
Experiment2: e = 1.5 for g1 = 100; e = 1 for g2 = 100
PSRMean 0.9405 0.6319 0.7819
PSR Var 0.0003 0.0005 0.0007
FDRMean 0.1560 0.2410 0.2051
FDR Var 0.0005 0.0009 0.0007
Left-side Experiment1: e = -0.5 for g1 = 100; e = -2 for g2 = 100
Experiment2: e = -1.5 for g1 = 100; e = -1 for g2 = 100
PSRMean 0.9400 0.6316 0.7871
PSR Var 0.0002 0.0004 0.0006
FDRMean 0.1605 0.2419 0.2024
FDR Var 0.0005 0.0007 0.0006
Two-sided Experiment1: e = -1 for g1 = 100; e = 1.5 for g2 = 100
Experiment2: e = 2 for g1 = 100; e = -1 for g2 = 100
PSRMean 0.9377 0.6670 0.7327
PSR Var 0.0003 0.0010 0.0007
FDRMean 0.1622 0.2270 0.2122
FDR Var 0.0005 0.0009 0.0007
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Table 2 The simulation settings and results for ﬁve platforms with continuous data
Method Multi-plat 1st ind. 2nd ind. 3rd ind. 4th ind. 5th ind.
Scenario 1: ρ = 0; g = g1 + g2 = 200
Exp1: e = 1.5 for g = 200
Exp2: e = 1.5 for g1 = 100; e = 1 for g2 = 100
Exp3: e = -0.5 for g1 = 100; e = -2 for g2 = 100
Exp4: e = -1 for g1 = 100; e = 1.5 for g2 = 100
Exp5: e = 2 for g1 = 100; e = -1 for g2 = 100
PSR Mean 0.9517 0.5601 0.4130 0.4464 0.4213 0.4471
PSR Var 0.0002 0.0012 0.0011 0.0004 0.0010 0.0005
FDR Mean 0.1572 0.2605 0.3299 0.3108 0.3205 0.2727
FDR Var 0.0004 0.0011 0.0018 0.0009 0.0010 0.0010
Scenario 2: ρ = 0.5; g = g1 + g2 = 200
Exp1: e = 1.5 for g = 200
Exp2: e = 1.5 for g1 = 100; e = 1 for g2 = 100
Exp3: e = -0.5 for g1 = 100; e = -2 for g2 = 100
Exp4: e = -1 for g1 = 100; e = 1.5 for g2 = 100
Exp5: e = 2 for g1 = 100; e = -1 for g2 = 100
PSR Mean 0.9998 0.8360 0.6655 0.5682 0.6712 0.5699
PSR Var 2.7e-06 0.0006 0.0010 0.0004 0.0010 0.0008
FDR Mean 0.1281 0.1898 0.2217 0.2593 0.2314 0.2093
FDR Var 0.0004 0.0006 0.0009 0.0007 0.0007 0.0008
those from 22, 26, 34 and 38 h represented the stationary
phase.
The objective of our analysis is now to select the
biomarkers that are diﬀerentially expressed between the
two phases. We apply our multi-platform integration
method to identify diﬀerentially expressed biomarkers.
For the mRNA data, we formulate the null hypothesis as
H0: the mRNA expression level is the same between the
two phases. Similarly, for protein data, the null hypothesis
is formulated asH0 : the protein ratio is the same between
the two phases. For both mRNA data and protein data,
two-sided alternatives are considered in the analysis. For
each platform, we use Student’s t-statistics to summarize
the statistical evidence, which are denoted as tm and tp.
To obtain the multivariate null distribution, 100 permu-
tations are conducted. The overall correlation between tm
and tp is 0.2787. The variances of tm and tp are 3.0489
and 3.6411, respectively. Based on the decision line con-
structed at the signiﬁcance level α = 0.05, our method
detects 172 diﬀerential expressed genes with an estimated
FˆP equal to 44. Individual analysis on the mRNA data and
the protein data detects 137 and 143 genes, respectively.
Figure 2 depicts the decision lines for all three compara-
tive analyses: the vertical lines using the mRNA data, the
horizontal lines using the protein data, and the dashed
lines using our multi-platform integration method.
Table 3 The simulation settings and results for two platforms with continuous data and discrete data
Methods
Multi-platform 1st individual 2nd individual
Experiment1: Continues; ρ = 0; e = 0.5 for g1 = 100; e = 2 for g2 = 100
Experiment2: Discrete; μqn1 = 5, e = 3 for g = 200
PSRMean 0.7356 0.5327 0.5228
PSR Var 0.0008 0.0004 0.0012
FDRMean 0.1967 0.2702 0.2763
FDR Var 0.0008 0.0012 0.0012
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Figure 1 Decision lines for comparing methods. Vertical lines use data from the ﬁrst individual platform, horizontal lines use data from the
second individual platform, and dashed lines use our multi-platform integration method. Circles represent non-diﬀerentially expressed biomarkers
and triangles represent diﬀerentially expressed biomarkers. Plots are based on one simulated data set and 100 permutations.
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Table 4 True positives and false discovery rates with
π = 0.8
Methods α 0.05 0.01 0.005
FˆP 40 8 4
multi-platform TˆP 224 165 143
(std) 6.5547 6.0820 5.5202
FP 44.8125 8.0250 3.8375
(std) 7.3348 3.4778 2.263
FDR 0.1563 0.0386 0.0214
(std) 0.0219 0.0161 0.0125
ˆFDR 0.1428 0.0388 0.0225
(std) 0.0041 0.0014 0.0009
1st individual TˆP 165 107 91
(std) 8.8797 5.3066 4.9031
FP 50.5125 9.9000 4.6500
(std) 8.9101 3.4982 2.1766
FDR 0.2431 0.0736 0.0406
(std) 0.0326 0.0246 0.0183
ˆFDR 0.1940 0.0600 0.0353
(std) 0.0103 0.0030 0.0019
2nd individual TˆP 197 106 79
(std) 7.2442 8.2303 6.3222
FP 48.9250 9.6000 5.000
(std) 7.1862 3.5750 2.5376
FDR 0.1986 0.0721 0.0506
(std) 0.0245 0.0258 0.0251
ˆFDR 0.1630 0.0607 0.0408
(std) 0.0060 0.0048 0.0033
Nine diﬀerentially expressed genes are identiﬁed by our
method but not by the other two methods. Among these,
we identify biosynthetic enzymes (SCO5080 actVA5,
SCO5072 actVIORFI) involved in actinorhodin produc-
tion. These genes are up-regulated only at late stages of
the culture and produce antibiotics during the stationary
phase. Expression of two genes encoding malate oxidore-
ductase (SCO2951) and translation elongation factor G
(SCO4661) have been found to be depressed during the
stationary phase compared with the growth phase [17].
Table 5 summarizes the nine genes and the associated
literature conﬁrmations [16-21].
Discussion
An ongoing problem in proteomics is that extremely small
sample sizes often occur, largely due to biological reasons.
To investigate the performance of our method in such
situations, we consider a case for each platform wherein
the control and the diseased groups each have only two
measurements. Our method is applied and the simula-
tion results shown in Table 6, scenario 1. Due to the
small sample size, the positive selection rate is rather low
and the false discovery rate rather high. Nevertheless, the
combined method still outperforms the single platform
method.
We also consider the situation in which data on the
same biomarker from n platforms have a multivariate
distribution and the data from the diseased group are
independent of those from the control group. The new
simulation results are summarized in Table 6, scenario 2.
The correlation between the platforms is set to 0.5, and
the other parameters are the same as in Table 1, scenario
1, right-sided test. Due to the high correlation among the
platforms, the gain in power of the aggregated method
is less pronounced than that of the independence case.
This is because diﬀerent platforms contribute overlapping
information when they are highly correlated.
The proposed method allows diﬀerent ways of con-
structing tm and tp as long as they provide summarized
statistical evidence for that platform. The Student’s t-
statistic is adopted in the paper simply for illustration
purpose. Alternatively, we can simply use the unstandard-
ized diﬀerences: tm = x1 − x2, and tp = y1 − y2. Then
we proceed with the randomization, obtain the estimated
variances for tm and tp and form a weighted linear sum
statistic. To compare the empirical performance of the











Figure 2 Decision lines for real data. Vertical lines use the mRNA
data, horizontal lines use the protein data, and dashed lines use our
multi-platform integration method.
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simulations under the setting 1 of Table 1 with right-sided
test. The results are summarized in Table 6, scenario 3.
The two versions have comparable performance in terms
of PSR and FDR. The unstandardized version of tm and tp
has a slightly higher PSR and a slightly lower FDR.
An alternative way of combining test statistics across
diﬀerent platforms is to form a multivariate quadratic
statistic. Given two platforms, for example, we consider an
alternative test statistic
tQ = (tm, tp)′ˆ−1(tm, tp),
where ˆ is the estimated covariance matrix of the vec-
tor (tm, tp) obtained from the empirical null distribution.
Such multivariate statistic can be used to test the over-
all null hypothesis against two-sided alternatives, while
the weighted linear statistic that we propose can be used
to test one-sided alternatives or two-sided alternatives.
Thus, our method is more broadly applicable. We fur-
ther conduct simulations to compare the multivariate
quadratic formwith our proposed weighted linear statistic
for two-sided tests under the setting of scenario 2, Table 1,
with results included in Table 7. For two-sided alterna-
tives, the quadratic statistic has very similar performance
to our proposed weighted linear statistic, with a slightly
lower PSR and a slightly higher FDR.
Finally, we compare our method with the existing robust
rank aggregation method [14] with results included in
Table 8. The inference from rank aggregation method is
based on the ranks of the test statistics. The ranking can
in some degree reﬂect the signiﬁcance of the test statistics.
But the position of the rank does not always translate into
the relatedness of the biomarker to the underlying bio-
logical mechanism. The rank aggregation method assigns
p-values of the observed ranks under the null hypothesis
that the normalized ranks of all biomarkers are uniformly
distributed. But this is a null hypothesis which can corre-
spond to two totally diﬀerent situations: all the biomarkers
are not related to the biological process or all of them are
related with equal eﬀect size. This evaluation of p-values
under such global null hypothesis has two implications.
First of all, if all the biomarkers are related to the biological
process with equal or similar eﬀect sizes, the observed
Table 5 SCO Summaries for the 9 genes which are identiﬁed bymulti-platform integrationmethod but not by individual
platform analysis
SCO Sanger Sanger Sanger Sanger TIGR Related
abbreviation annotation category subcategory category paper*
SCO1958 uvrA ABC excision Macromolecule DNA-replication, excinuclease ABC, [17]
nuclease subunit A metabolism repair, restr./modiﬁc’n A subunit [17]
SCO2940 other putative Not classiﬁed Not classiﬁed xanthine
oxidoreductase (included putative (included putative dehydrogenase,
assignments) assignments) putative
SCO2951 other putative malate Central intermediary Other central malate [16,17,19]
oxidoreductase metabolisms intermediary metabolism oxidoreductase
SCO3094 other conserved hypothetical Conserved in conserved
hypothetical protein organism other than hypothetical
protein protein Escherichia coli protein
SCO4661 fusA elongation Macromolecule Proteins - translation [16,17,19]
factor G metabolism translation and elongation
modiﬁcation factor G
SCO5072 actVIORF1 hydroxylacyl-CoA Secondary PKS hydroxylacyl-CoA [16,17,20]
dehydrogenase metabolism PKS dehydrogenase
SCO5080 actVA5 putative Secondary PKS putative [17,18]
hydrolase metabolism PKS hydrolase
SCO6219 Other putative ATP/GTP Protein Serine/ [17]
binding protein, kinases threonine
putative serine
SCO6222 other putative Not classiﬁed Not classiﬁed aminotransferase, [15,17]
aminotransferase (included putative (included putative class I
assignments) assignments)
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Table 6 Additional simulations
Method Multi-plat 1st ind. 2nd ind.
Scenario 1: Extremely small sample size
two measurements from each group
PSRMean 0.3022 0.2363 0.2179
PSR Var 0.0009 0.0006 0.0007
FDRMean 0.3782 0.4436 0.4694
FDR Var 0.0023 0.0025 0.0027
Scenario 2: Correlation among platforms set to 0.5
Disease and normal groups are independent
PSRMean 0.6689 0.5365 0.5578
PSR Var 0.0009 0.0008 0.0011
FDRMean 0.2255 0.2690 0.2641
FDR Var 0.0008 0.0010 0.0010
Scenario 3: Non-standardized version of tm and tp
i.e. tm = x2 − x1, tp = y2 − y1
PSRMean 0.8142 0.5479 0.5992
PSR Var 0.0009 0.0005 0.0010
FDRMean 0.1586 0.2358 0.2235
FDR Var 0.0006 0.0011 0.0010
ranks will appear non-informative and thus the method
will have little power to detect them. Secondly, the p-value
of each observed rank is calculated under the global null
hypothesis. Thus, the rank aggregation has a correct error
control under the global null hypothesis but has no correct
Table 7 Comparison with the quadratic test statistic tQ
Method Multi-plat Quadratic
PSRMean 0.9377 0.9155
PSR Var 0.0003 0.0004
FDRMean 0.1622 0.1804
FDR Var 0.0005 0.0005
Quadratic: Exp1: e = -1 for g1 = 100; e = 1.5 for g2 = 100
Exp2: e = 2 for g1 = 100; e = -1 for g2 = 100
error control under other conﬁgurations of the individual
hypotheses. In other words, it lack the strong control of
the error rate under diﬀerent conﬁgurations of the indi-
vidual hypothesis [15]. On the other hand, our method
assigns p-values under the individual null hypotheses and
thus have a strong control of the error rate. This means
our method’s actual false discovery rate and estimated
false discovery rate will be in good agreement no mat-
ter how many of the genes belong to the null situation
and how many belong to the alternative situation. While
in contrast, the rank aggregation will tend to be very
conservative if there are many biomarkers belonging to
the alternative situation. To demonstrate this, we choose
the number of signiﬁcant markers ranging from 100, 200
to 400. It is shown in Table 8 that the rank aggrega-
tion behaves very conservatively in the presence of large
number of signiﬁcant markers. For instance, with ﬁve
platforms and 200 signiﬁcant biomarkers, our proposed
Table 8 Comparison with Robust Rank AggregationMethod
Setting: Method Multi-plat RRA
1. ρ = 0.5; g = g1 + g2 = 100
Exp1: e = 1.5 for g = 200 PSRMean 1.000 0.7497
Exp2: e = 1.5 for g1 = 100; e = 1 for g2 = 100 PSR Var 1.98e-6 0.0012
Exp3: e = -0.5 for g1 = 100; e = -2 for g2 = 100 FDRMean 0.2803 0.0912
Exp4: e = -1 for g1 = 100; e = 1.5 for g2 = 100 FDR Var 0.0011 0.0003
Exp5: e = 2 for g1 = 100; e = -1 for g2 = 100
2. ρ = 0.5; g = g1 + g2 = 200
Exp1: e = 1.5 for g = 100 PSRMean 0.9995 0.4995
Exp2: e = 1.5 for g1 = 50; e = 1 for g2 = 50 PSR Var 0.23e-06 0.0008
Exp3: e = -0.5 for g1 = 50; e = -2 for g2 = 50 FDRMean 0.1399 0.0823
Exp4: e = -1 for g1 = 50; e = 1.5 for g2 = 50 FDR Var 0.0004 0.0004
Exp5: e = 2 for g1 = 50; e = -1 for g2 = 50
3. ρ = 0.5; g = g1 + g2 = 400
Exp1: e = 1.5 for g = 100 PSRMean 0.9992 0.1133
Exp2: e = 1.5 for g1 = 50; e = 1 for g2 = 50 PSR Var 2.23e-6 0.0002
Exp3: e = -0.5 for g1 = 50; e = -2 for g2 = 50 FDRMean 0.0402 0.0796
Exp4: e = -1 for g1 = 50; e = 1.5 for g2 = 50 FDR Var 0.0001 0.0015
Exp5: e = 2 for g1 = 50; e = -1 for g2 = 50
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method has a PSR of 0.9995 and a FDR of 0.1399, while
the competing rank aggregationmethod has a much lower
PSR of 0.4995 and FDR of 0.0823. This comparison further
demonstrates the advantage of the proposed method.
Conclusion
With the advent of various types of genomic technolo-
gies, it is imperative to develop a method that can inte-
grate diﬀerent types of genomic data to solve biological
questions. We develop a general framework for data inte-
gration across multiple data platforms. For each data
set, a test statistic is formed to summarize the statistic
evidence toward the speciﬁc null hypothesis tailored to
the data platform. The types of test statistics can vary
and their marginal distributions can be diﬀerent. The
observed test statistics can then be aggregated across dif-
ferent data platforms. The overall decision is based on the
empirical distribution of the aggregated statistic obtained
through random permutations. Our method can accom-
modate diﬀerent experimental designs and various data
types across platforms.
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